Provided By GlobeNewswire
Last update: Jan 10, 2025
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.
Read more at globenewswire.comNASDAQ:GHRS (6/4/2025, 8:00:01 PM)
12.43
+0.35 (+2.9%)
Find more stocks in the Stock Screener